Cookie Notification

We use cookies to personalize your experience. Learn more here.

I Accept
I Don't Accept

News

Police can search DNA websites

Published on 11/16/2019 @ 1 AM EST

A judge issued a warrant that allowed a Florida detective full access to DNA profiles of millions of users at once. This included users who hadn’t opted in for making their DNA available for searches. Police have already used DNA website GEDMatch to catch the Golden State Killer.

Lyft adds 200 EVs to fleet

Published on 11/16/2019 @ 1 AM EST

In a blog post, Lyft says it's “working toward a fully electric future,” with step one being a launch of 200 electric vehicles in Denver. Citing EV cost as prohibitive, the vehicles will be an available option for Lyft drivers instead of their conventional vehicles.

Apple debuts Research app for health

Published on 11/15/2019 @ 9 AM EST

After Stanford declares the Apple Watch can accurately detect heart issues, Apple is now running three new research studies including women’s health, movement, and hearing. The smartwatch will gather data from the users after they answer a series of questions.

Stanford publishes Apple Watch HR study

Published on 11/14/2019 @ 10 AM EST

Featuring heart-rate data collected from Apple Watch users, Standford’s paper in the New England Journal of Medicine concludes the Apple Watch is able to detect atrial fibrillation. This is a condition that causes heart failure, blood clots, and stroke. The study included 400,000 volunteers.

Google patient data app under investigation

Published on 11/13/2019 @ 9 AM EST

Project Nightingale is a partnership with Ascension that gives Google access to individuals’ medical records. As soon as it was announced, the Office for Civil Rights stated it will begin a federal inquiry to ensure the project is entirely HIPAA compliant.

EU approves Ebola vaccine

Published on 11/12/2019 @ 9 AM EST

After the 2014 outbreak in West Africa, Ervebo is an Ebola vaccine acquired by Merck that has been granted “conditional marketing authorization.” It’s the first to receive EU approval and this type of approval requires less comprehensive testing.